Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...

Global demand for Lilly's and Danish rival Novo Nordisk's diabetes and weight-loss drugs has been extraordinary, with the two ...

From STAT’s Elaine Chen: A federal judge this week ruled against a compounding trade group that wanted to continue making ...

Very few people are currently being prescribed drugs for weight loss on the NHS in Scotland, research by BBC Scotland News ...

This month pharmacies will no longer be allowed to sell lower-cost compounded versions of the anti-obesity drug tirzepatide — ...

Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...

Cambridge synthetic biology doyen Constructive Bio has been awarded a significant grant from Innovate UK to transform the ...

Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong ...

The health regulator announced last month that there was no longer a shortage of Novo's Wegovy and diabetes drug Ozempic, ...